Lighthouse receives $49.2 million NIA grant to advance phase 2 study of Alzheimer’s disease
LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
This authorization follows FDA approval in June and WHO’s July recommendation adding twice-yearly lenacapavir as a PrEP option
AiMeD noted that proposed GST changes—to either 5% or 18%—both present significant risks requiring carefully nuanced consideration
Protein L is known as a “superantigen” because it can bind antibodies in unusual ways
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
The company has improved access to quality healthcare for seniors across both urban and rural areas
The facility will be positioned as a Centre of Excellence for tertiary care services
The patient had been battling DFSP for over eight years, enduring multiple recurrences despite three previous surgeries
Subscribe To Our Newsletter & Stay Updated